Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCI/bupropion HCI) Extended-Release Tablets, which is approved in the United States. Orexigen’s partner for North America, Takeda Pharmaceuticals, markets CONTRAVE in the United States.
Outside of North America, Orexigen's strategy for naltrexone HCI /bupropion HCI is to pursue marketing authorizations worldwide and pharmaceutical partnerships for global commercialization. Orexigen has submitted an application for marketing authorization for MysimbaTM (naltrexone HCl /bupropion HCl prolonged release) in Europe. Mysimba received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in December 2014, with potential approval by the European Commission in early 2015.